TLPH → $3.50 by Dec 23, 2026.

Hi everyone, So Talphera (previously AcelRx) is currently testing Nafamostat, a regional anticoagulant medication used during CRRT, whereas no medication has this ability (citrate is not FDA approved for CRRT). They need 70 patients total, and the last quarter they announced about 61% patients signed up. They did push the date from finishing trial around july/August to end of year (with FDA approval now in early next year). There was a ton of insider purchasing lately despite them having the …